查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945914

糖尿病酮酸症市場－全球產業規模、佔有率、趨勢、機會及預測（依療法、最終用戶、地區及競爭格局分類，2021-2031年）

Diabetic Ketoacidosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球糖尿病酮酸症市場預計將從 2025 年的 33.7 億美元成長到 2031 年的 46.8 億美元，複合年成長率達到 5.63%。

該市場涵蓋了治療這種危及生命的代謝性疾病所需的關鍵診斷和治療藥物，例如輸液療法、電解質管理方案和靜脈注射胰島素。推動這一市場成長的關鍵因素是全球糖尿病盛行率的不斷上升，這顯著增加了面臨高血糖緊急情況風險的患者數量。根據國際糖尿病聯盟 (IDF) 預測，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，這一數字凸顯了對有效急性護理措施的巨大且日益成長的需求。不斷加重的疾病負擔，加上現有患者對胰島素治療的依從性較低，進一步推動了對這些關鍵醫療產品的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 33.7億美元
市場規模：2031年 46.8億美元
複合年成長率：2026-2031年 5.63%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

然而，限制整體市場成長的主要障礙是專科治療方案和重症監護住院治療的高昂費用。在許多開發中國家，基本診斷工具和先進醫療基礎設施的匱乏進一步限制了有效醫療服務的提供。因此，儘管糖尿病發病率的上升為市場擴張奠定了堅實的基礎，但中低收入地區醫療資源分配不均和經濟障礙仍然是公平獲得治療和全球整體成長的重大阻礙。

市場促進因素

速效胰島素療法的需求不斷成長是全球糖尿病酮酸症(DKA) 市場的主要促進因素。隨著高血糖緊急情況發生率的增加，作為 DKA 臨床管理核心的強化胰島素療法的需求在全球範圍內持續成長。主要治療藥物生產商的強勁商業性表現進一步強化了這一趨勢，凸顯了這些救命藥物的重要性。例如，諾和諾德公司於 2025 年 2 月發布的《2024 年年度報告》預測，2024 年胰島素總銷售額將成長 15.3%，顯示人們越來越依賴胰島素產品來應對嚴重的代謝併發症。

同時，照護現場酮體監測和連續診斷解決方案的技術進步也在推動市場擴張。主動疾病管理的趨勢正在加速先進感測器設備的普及，這些設備能夠早期檢測酮症，從而降低嚴重住院的風險並改善患者預後。根據雅培公司於2025年1月發布的“2024年第四季度及全年業績報告”，其糖尿病護理產品銷售額在第四季度成長了22.7%，表明新一代監測技術正在被迅速採用。更廣泛的行業趨勢也進一步支撐了這一強勁領域的成長。禮來公司在2025年1月報告稱，由於全球對綜合糖尿病護理產品的需求不斷成長，其2024年全年全球收入成長了32%。

市場挑戰

與特殊治療方案和重症監護住院相關的巨額經濟負擔，嚴重阻礙了全球糖尿病酮酸症市場的擴張。妥善管理這種疾病需要昂貴的醫療資源，包括嚴格的液體療法、持續胰島素輸注系統和持續的檢查室監測。在資源匱乏的地區，醫療機構缺乏維持這些昂貴通訊協定的預算，導致大多數患者無法獲得這些重要的診斷和治療方法。這種經濟差距使得臨床需求無法轉化為實際效益，阻礙了高疾病負擔發展中地區的市場滲透。

這種經濟限制因素因糖尿病治療本身所需的高昂費用而加劇，這對各國醫療預算帶來了巨大壓力。國際糖尿病聯盟報告稱，到2024年，全球糖尿病醫療支出將超過1兆美元。如此高昂的支出迫使許多醫療系統重新分配資源，優先考慮基礎維護護理而非專科急診護理。因此，不斷上漲的醫療成本阻礙了經濟困難市場獲得基本醫療產品的途徑，直接限制了全球醫療產業的成長。

市場趨勢

自動化閉合迴路胰島素輸注系統的普及正在改變全球糖尿病酮酸症市場的預防性治療模式，其透過自動調整基礎胰島素劑量來預防高血糖危象。與傳統的多次注射療法不同，這些混合閉合迴路設備利用連續血糖數據，透過演算法自動調整或停止胰島素劑量，在1型和2型糖尿病患者出現酮症之前進行直接干預。這種向自動化預防性治療的轉變正在推動其商業性應用的顯著成長。 Insulet公司在2024年11月發布的2024年第三季財報中指出，受其自動化給藥平台快速成長的推動，季度營收成長25.7%至5.439億美元。

此外，將人工智慧 (AI) 應用於預測性血糖分析，能夠在代謝補償發生前數小時識別糖尿病酮酸症(DKA) 的風險因素，從而從根本上改變臨床策略。胰島素管理生態系中的先進演算法分析歷史血糖值趨勢，預測嚴重高血糖事件，並發出警報，提示及時進行預防性胰島素或輸液，以穩定患者的生理功能。這種朝向智慧化、數據驅動的疾病管理模式的轉變，正在加速智慧糖尿病技術的應用。根據Medtronic於 2024 年 11 月發布的“2025 會計年度第二季度財務業績報告”，其糖尿病部門的銷售額成長了 12.4%，達到 6.86 億美元，凸顯了市場向算法增強型預測系統的轉變。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球糖尿病酮酸症市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（胰島素治療、電解質補充、液體補充）
    • 按最終使用者（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美糖尿病酮酸症市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲糖尿病酮酸症市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區糖尿病酮酸症市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲糖尿病酮酸症市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲糖尿病酮酸症市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球糖尿病酮酸症市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novo Nordisk AS
  • Baxter Healthcare Corporation
  • B. Braun Medical Inc.
  • ICU Medical, Inc.
  • Pfizer Inc.
  • Merit Pharmaceutical
  • SteriCare Solutions
  • Soxa Formulations & Research（Pvt.）Ltd
  • BD company
  • Fresenius Kabi USA LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17286

The Global Diabetic Ketoacidosis Market is projected to expand from USD 3.37 Billion in 2025 to USD 4.68 Billion by 2031, achieving a compound annual growth rate of 5.63%. This market covers essential diagnostics and therapeutics, such as fluid replacement therapies, electrolyte management solutions, and intravenous insulin, all of which are vital for treating this life-threatening metabolic condition. A major factor driving this growth is the rising global prevalence of diabetes, which significantly increases the number of patients at risk for hyperglycemic emergencies. According to the International Diabetes Federation, there were roughly 589 million adults living with diabetes globally in 2024, a figure that highlights the substantial and growing need for effective acute care measures. This rising disease burden, combined with frequent insulin non-compliance among existing patients, reinforces the sustained demand for these critical medical products.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.37 Billion
Market Size 2031USD 4.68 Billion
CAGR 2026-20315.63%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Conversely, a major hurdle restricting broader market growth is the substantial expense linked to specialized treatment regimens and intensive care hospitalization. In many developing countries, restricted access to essential diagnostic tools and advanced healthcare infrastructure further limits the effective provision of care. As a result, although the increasing incidence of diabetes provides a solid basis for market expansion, healthcare disparities and financial barriers in low-to-middle-income regions persist as significant obstacles to equitable treatment access and overall global growth.

Market Driver

The escalating need for rapid-acting insulin therapies acts as a primary catalyst for the Global Diabetic Ketoacidosis Market. As hyperglycemic emergencies become more frequent, the demand for intensive insulin regimens-which are central to clinical DKA management-continues to grow worldwide. This trend is reinforced by the strong commercial results of leading therapeutic manufacturers, underscoring the vital importance of these life-saving medications. For instance, Novo Nordisk's 'Annual Report 2024', released in February 2025, revealed that total insulin sales rose by 15.3% in 2024, demonstrating the increasing reliance on essential insulin products to handle severe metabolic complications.

Simultaneously, market expansion is being driven by technological progress in point-of-care ketone monitoring and continuous diagnostic solutions. The transition toward proactive disease management has accelerated the use of advanced sensor-based devices that allow for the early detection of ketosis, thereby lowering the likelihood of severe hospitalization and enhancing patient outcomes. According to Abbott's 'Fourth-Quarter and Full-Year 2024 Results' from January 2025, Diabetes Care sales increased by 22.7% in the fourth quarter, indicating a swift adoption of next-generation monitoring technologies. This strong sector growth is further supported by wider industry trends; Eli Lilly and Company reported in January 2025 that their full-year 2024 worldwide revenue jumped by 32%, fueled by the surging global demand for comprehensive diabetes care products.

Market Challenge

The significant financial strain associated with specialized treatment regimens and intensive care hospitalization poses a major obstacle to the expansion of the Global Diabetic Ketoacidosis Market. Successfully managing this condition requires costly medical resources, such as rigorous fluid resuscitation, continuous insulin delivery systems, and persistent laboratory monitoring. In resource-constrained environments, healthcare facilities often lack the necessary budget to sustain such expensive protocols, making these critical diagnostics and therapeutics unreachable for a vast portion of the patient population. This gap in affordability stops clinical needs from translating into actual revenue, thereby limiting market penetration in developing regions with a high disease burden.

This economic limitation is further intensified by the massive expenditures already required for general diabetes care, which places a heavy strain on national healthcare budgets. As reported by the International Diabetes Federation, global health expenditure related to diabetes exceeded USD 1 trillion in 2024. Such high spending levels compel many healthcare systems to ration resources, often favoring basic maintenance over specialized emergency interventions. Consequently, the high cost of care restricts the uptake of essential medical products in economically challenged markets, directly hindering the overall growth of the global sector.

Market Trends

The uptake of Automated Closed-Loop Insulin Delivery Systems is reshaping the preventive landscape of the Global Diabetic Ketoacidosis Market by automating basal insulin modulation to prevent hyperglycemic crises. Distinct from traditional multiple daily injection therapies, these hybrid closed-loop devices employ continuous glucose data to algorithmically adjust or suspend insulin delivery, thereby intervening directly before the onset of ketosis in Type 1 and Type 2 diabetes patients. This therapeutic transition toward automated preventive care is fueling significant commercial adoption; Insulet Corporation reported in its 'Third Quarter 2024 Financial Results' in November 2024 that quarterly revenue rose by 25.7% to USD 543.9 million, driven by the rapid growth of its automated delivery platform.

Additionally, the integration of Artificial Intelligence for Predictive Glycemic Analytics is fundamentally altering clinical strategies by allowing for the identification of DKA risk factors hours prior to metabolic decompensation. Advanced algorithms within insulin management ecosystems now examine historical glycemic trends to forecast severe hyperglycemic events, generating alerts that trigger preemptive insulin or fluid administration to stabilize patient physiology. This shift toward intelligent, data-driven disease management is hastening the adoption of smart diabetes technologies; according to Medtronic's 'Second Quarter Fiscal Year 2025 Financial Results' from November 2024, diabetes segment revenue increased by 12.4% to USD 686 million, highlighting the market's shift toward algorithm-enhanced predictive systems.

Key Market Players

  • Novo Nordisk AS
  • Baxter Healthcare Corporation
  • B. Braun Medical Inc.
  • ICU Medical, Inc.
  • Pfizer Inc.
  • Merit Pharmaceutical
  • SteriCare Solutions
  • Soxa Formulations & Research (Pvt.) Ltd
  • BD company
  • Fresenius Kabi USA LLC

Report Scope

In this report, the Global Diabetic Ketoacidosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Ketoacidosis Market, By Treatment

  • Insulin Therapy
  • Electrolyte Replacement
  • Fluid Replacement

Diabetic Ketoacidosis Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Diabetic Ketoacidosis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Ketoacidosis Market.

Available Customizations:

Global Diabetic Ketoacidosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetic Ketoacidosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Diabetic Ketoacidosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetic Ketoacidosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Diabetic Ketoacidosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Diabetic Ketoacidosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Diabetic Ketoacidosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diabetic Ketoacidosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. France Diabetic Ketoacidosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Diabetic Ketoacidosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Diabetic Ketoacidosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Diabetic Ketoacidosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia Pacific Diabetic Ketoacidosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetic Ketoacidosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. India Diabetic Ketoacidosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Diabetic Ketoacidosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Diabetic Ketoacidosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Diabetic Ketoacidosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. Middle East & Africa Diabetic Ketoacidosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diabetic Ketoacidosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Diabetic Ketoacidosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Diabetic Ketoacidosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. South America Diabetic Ketoacidosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diabetic Ketoacidosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Diabetic Ketoacidosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Diabetic Ketoacidosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetic Ketoacidosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk AS
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter Healthcare Corporation
  • 15.3. B. Braun Medical Inc.
  • 15.4. ICU Medical, Inc.
  • 15.5. Pfizer Inc.
  • 15.6. Merit Pharmaceutical
  • 15.7. SteriCare Solutions
  • 15.8. Soxa Formulations & Research (Pvt.) Ltd
  • 15.9. BD company
  • 15.10. Fresenius Kabi USA LLC

16. Strategic Recommendations

17. About Us & Disclaimer